The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMRX | +180.93% | N/A | N/A | -66% |
| S&P | +16.9% | +95.99% | +14.39% | +55% |
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.09M | 47.7% |
| Market Cap | $121.27M | 219.5% |
| Market Cap / Employee | $2.25M | 0.0% |
| Employees | 54 | 0.0% |
| Net Income | -$14.43M | -2.5% |
| EBITDA | -$14.67M | 0.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.36M | -55.9% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.63M | -9.2% |
| Short Term Debt | $0.37M | 17.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -106.07% | -50.6% |
| Return On Invested Capital | -60.71% | -11.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.45M | 18.3% |
| Operating Free Cash Flow | -$9.45M | 18.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.11 | 1.18 | 1.14 | 2.90 | 501.06% |
| Price to Tangible Book Value | 1.25 | 1.35 | 1.37 | 3.48 | 557.71% |
| Enterprise Value to EBITDA | -1.85 | -1.98 | -1.45 | -6.74 | -669.32% |
| Return on Equity | -71.8% | -92.5% | -102.5% | -130.5% | 111.07% |
| Total Debt | $4.24M | $4.16M | $4.08M | $4.00M | -7.22% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
